- Home
- INDV
INDV
Indivior PLC
as 10-17-2024 4:00pm EST
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $15.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.33 - $23.22 | Next Earning Date: | 11-07-2024 |
| Revenue: | $1,147,000,000 | Revenue Growth: | 14.47% |
| Revenue Growth (this year): | 9.52% | Revenue Growth (next year): | 3.59% |
Latest Indivior PLC News
INDV Breaking Stock News: Dive into INDV Ticker-Specific Updates for Smart Investing
GuruFocus.com
5 hours ago
Two Seas Capital LP Increases Stake in Indivior PLC
TipRanks
6 days ago
Indivior price target lowered to $16 from $20 at Craig-Hallum
GuruFocus.com
7 days ago
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...
Benzinga
8 days ago
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
MT Newswires
8 days ago
Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook
PR Newswire
8 days ago
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
MT Newswires
10 days ago
Indivior Gets FDA Priority Review on Prior Approval Supplement for Sublocade
PR Newswire
10 days ago
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
Compare INDV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INDV Indivior PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.